Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662448 · ClinicalTrials.gov registry record · NA
Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies
A NA study of Optic Neuropathy, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06662448: Recruiting NA study of Optic Neuropathy, sponsored by NYU Langone Health.
NCT06662448 is a NA study of Optic Neuropathy that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06662448, a NA study of Optic Neuropathy, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of home-based rtACS to ameliorate the progressive effects of vision loss functionally in the eye and the visual pathway, and in regard to people's independence (i.e., functional ability).
Primary Outcome
Outcome measure will be assessed using Optical coherence tomography (OCT).
Conditions Studied
Interventions
- DEVICE SAVIR Alpha Synch mobile (SASm)
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2029-05-18 |
| Phase | NA |
What NCT06662448 shows while recruiting
NCT06662448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Optic Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which SAVIR Alpha Synch mobile (SASm) is the first listed.
NCT06662448 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06662448 about?
NCT06662448 is a clinical study titled "Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies". The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of h...
What is the current status of trial NCT06662448?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-11-18. Estimated completion is 2029-05-18.
What conditions does trial NCT06662448 study?
This clinical trial studies the following conditions: Optic Neuropathy.
What interventions are being tested in trial NCT06662448?
The interventions under investigation include: SAVIR Alpha Synch mobile (SASm) (DEVICE).
Who is sponsoring clinical trial NCT06662448?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06662448 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Optic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06662448's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI